Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).

Trials · 2020 · PMC7001267 · PMID 32019575

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The DHA-enriched formula inhibited NT-proB-type natriuretic peptide (NT-ProBNP) plasmatic elevation after doxorubicin chemotherapy (48 h), suggesting a subclinical cardiotoxicity attenuation and showed a trend towards a lower LVEF decline at 10–12 months when compared to the placebo group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.